Mesoblast

Latest news

• Mesoblast Limited (ASX:MSB) Builds Ryoncil Revenue Base as FY26 Loss Narrows (opens in a new tab)

  Kalkine · Oct 1, 2026

• State Street Group Cuts Mesoblast Stake Below Substantial Holder Threshold (opens in a new tab)

  TipRanks · Oct 1, 2026

• Mesoblast Subject to State Street Substantial Holder Cessation Notice (opens in a new tab)

  Kalkine · Oct 1, 2026

• Why Are Mesoblast (ASX:MSB) Shares Slipping Despite FDA Approval? (opens in a new tab)

  Kalkine Media · Oct 1, 2026

• Mesoblast Limited Subject to New Substantial Holder Notice from State Street Corporation (opens in a new tab)

  Kalkine · Sep 30, 2026

• Has Mesoblast (ASX:MSB) Cleared a Key FDA Manufacturing Hurdle for Ryoncil? (opens in a new tab)

  Kalkine Media · Sep 30, 2026

• Mesoblast Limited Sponsored ADR Statistics – HAN:LWB1 (opens in a new tab)

  TradingView · Sep 29, 2026

• ETFs Investing in Mesoblast Limited Sponsored ADR Stocks (opens in a new tab)

  TradingView · Sep 29, 2026

• What Sets Pro Medicus, Mesoblast and Harvey Norman Apart? (opens in a new tab)

  Kalkine Media · Sep 29, 2026

• Has Mesoblast (ASX:MSB) cleared a key FDA manufacturing hurdle? (opens in a new tab)

  Kalkine Media · Sep 28, 2026

• Could Mesoblast shares rise over 100% in 12 months? (opens in a new tab)

  The Motley Fool Australia · Sep 27, 2026

• MEOBF Form 4 Filings - MESOBLAST LTD SEC Form 4 (opens in a new tab)

  Stock Titan · Sep 27, 2026

• Mesoblast (ASX:MSB) Secures FDA Approval for New Ryoncil Potency Assay (opens in a new tab)

  Kalkine · Sep 26, 2026

• Mesoblast (ASX:MSB) Stock Forecast & Analyst Predictions (opens in a new tab)

  Simply Wall Street · Sep 25, 2026

• Mesoblast (NASDAQ: MESO) Secures FDA Approval for TIBA Potency Assay in Ryoncil Production (opens in a new tab)

  Kalkine Media · Sep 24, 2026

• Mesoblast wins FDA nod for new potency assay for Ryoncil (opens in a new tab)

  Seeking Alpha · Sep 24, 2026

• Cantor Fitzgerald reiterates Mesoblast stock rating on adult trial focus (opens in a new tab)

  Investing.com · Sep 24, 2026

• Mesoblast receives FDA approval for new potency assay for Ryoncil (opens in a new tab)

  Investing.com · Sep 24, 2026

• Mesoblast (ASX:MSB): The Developments Investors Are Watching After FDA Approval for Ryoncil Potency Assay (opens in a new tab)

  Kalkine · Sep 24, 2026

• Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product (opens in a new tab)

  The Manila Times · Sep 24, 2026

• Every new batch of Mesoblast (NASDAQ: MESO)'s cell therapy will face another check after FDA approval. (opens in a new tab)

  Stock Titan · Sep 24, 2026

• Mesoblast Says FDA Approves New Potency Assay For Commercial Ryoncil (opens in a new tab)

  TradingView · Sep 24, 2026

• Mesoblast wins FDA nod for new Ryoncil potency test (opens in a new tab)

  The Motley Fool Australia · Sep 24, 2026

• Mesoblast Receives FDA Approval for New RYONCIL Potency Assay (opens in a new tab)

  Kalkine · Sep 24, 2026

• ASX Healthcare Stocks to Watch in September 2026: Sigma Healthcare (ASX:SIG), Neuren Pharmaceuticals (ASX:NEU) and Mesoblast (ASX:MSB) (opens in a new tab)

  Kalkine · Sep 14, 2026

• Sigma Healthcare, Neuren and Mesoblast: Financial Performance Across ASX Healthcare (opens in a new tab)

  Kalkine · Sep 14, 2026

• Mesoblast (ASX: MSB) — Clinical Milestones and Commercial Ambitions: Why This Biotech Is in Focus (opens in a new tab)

  Kalkine · Sep 7, 2026

• Mesoblast (ASX:MSB): Ryoncil Revenue and Pipeline Expansion Redefine the Commercial Story (opens in a new tab)

  Kalkine · Sep 7, 2026

• Mesoblast (ASX:MSB): What Could Drive Its Next Move? (opens in a new tab)

  Kalkine Media · Sep 4, 2026

• Mesoblast (ASX:MSB) Holds Steady — Is Ryoncil's US Launch Enough to Watch This Biotech? (opens in a new tab)

  Kalkine · Sep 4, 2026